COL18A1 and colorectal carcinoma: Jia et al. (2004) reported that endostatin slowed or even stopped tumor growth, but when treatment stopped, tumors began to re-grow rapidly. Pleasingly, we found that B. longum as a delivery system to carry endostatin showed long-term safety and efficacy for colon cancer. When administration with B. longum-Endo stopped, the primary tumor did not grow, and the mouse’s overall survival rate was also improved. We thus concluded that the combination of B. longum and endostatin showed self-amplifying, synergistic anti-inflammation, and anti-tumor effects in CRC.